NanoPhoria Bioscience is a Milan-based biotech company specializing in the development of a nano-in-micro and lung-to-heart delivery platform utilizing inorganic calcium phosphate nanoparticles. The company's lead product, NP-MP1, is a first-in-class peptide designed to target cardiac L-type calcium channels, aiming to improve ejection fraction in patients with heart failure with reduced ejection fraction (HFrEF). NanoPhoria's innovative platform seeks to address unmet medical needs by enhancing cardiac contractility and offering new treatment paradigms for cardiovascular and other chronic diseases.